Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Novo Nordisk A/S ADR (NY: NVO ) 116.46 -1.55 (-1.31%) Streaming Delayed Price Updated: 10:48 AM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Novo Nordisk A/S ADR < Previous 1 2 3 4 5 6 7 8 9 ... 58 59 Next > Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges Today 10:37 EDT Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed. Via Benzinga Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries Today 9:06 EDT Eli Lilly announces a $4.5B investment to build the Lilly Medicine Foundry, a state-of-the-art facility in Indiana. The new center will focus on advanced drug development and manufacturing, reinforcing... Via Benzinga Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation Today 7:02 EDT Eli Lilly is on track to become the first trillion-dollar pharma company, fueled by FDA-approved weight loss drugs. With a current valuation of $842 billion, analysts weigh investor risks as... Via Benzinga US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next October 01, 2024 HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... Via Benzinga Topics Economy Exposures Interest Rates If You Invested $1000 In This Stock 5 Years Ago, You Would Have $4,700 Today September 27, 2024 Via Benzinga Novo Nordisk's Options: A Look at What the Big Money is Thinking September 24, 2024 Via Benzinga Novo Nordisk's Options: A Look at What the Big Money is Thinking September 23, 2024 Via Benzinga Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential September 30, 2024 Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales. The company aims to launch 20 transformative drugs by 2030 while cutting... Via Benzinga Investors should take note of NYSE:NVO, a growth stock that remains attractively priced. September 30, 2024 While growth is established for NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), the stock's valuation remains reasonable. Via Chartmill 'Stop Ripping Us Off' – Incredibly, Elon Musk And Bernie Sanders Seem To Agree On This One Thing – 'I Really Am With Bernie On This One' September 29, 2024 Via Benzinga Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years September 28, 2024 These two players are set on finding the next big therapeutic modality. Via The Motley Fool Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major Stablecoin Tease September 28, 2024 Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. The Dow Jones Industrial Average hit a record high Friday as investors... Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities Latest Inflation Data Cements Fed's Interest Rate Call, S&P 500 Hits All-Time High, Biden Adviser Backs China EV Ban At Detroit Economic Club: This Week In The Markets September 27, 2024 Inflation data supports another 0.5% interest rate cut in November, says RSM US LLP Chief Economist Joseph Brusuelas. S&P 500 hits all-time high. Brainard supports China EV ban. Meta Platforms unveils... Via Benzinga Topics Artificial Intelligence Economy Stocks Exposures Artificial Intelligence Interest Rates US Equities Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales September 27, 2024 Novo Nordisk stock fell after a JPMorgan analyst said sales of its blockbuster weight-loss drug may be weaker-than-expected. Via Investor's Business Daily Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session September 27, 2024 Via Benzinga Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy? September 27, 2024 The thrust of the company's long-term strategy is becoming clearer. Via The Motley Fool Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development September 26, 2024 Evotec and Novo Nordisk have partnered to develop off-the-shelf cell therapy products. The collaboration will focus on advancing stem cell-based therapies for potential commercialization. Via Benzinga Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead September 26, 2024 Even the mighty Novo Nordisk can't hold a candle to its peer in this area. Via The Motley Fool EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia September 26, 2024 Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial will assess safety, tolerability, and weight loss outcomes, with data expected... Via Benzinga Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why. September 26, 2024 The healthcare company's pivot into a new set of technologies will have many implications for the stock. Via The Motley Fool Lose Weight With Novo Nordisk Drugs, Gain Money With Stock September 25, 2024 If understood an applied correctly, technical analysis is the study or investor and trader psychology. The chart of NVO shows this. Via Benzinga Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users September 25, 2024 A new study suggests semaglutide drugs like Ozempic, used for type 2 diabetes, may lower the risk of opioid overdose in patients with opioid use disorder. Findings highlight the need for more research... Via Benzinga Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes September 25, 2024 Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose. Via Benzinga Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability September 25, 2024 2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval... Via Benzinga Exposures Product Safety EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' September 25, 2024 Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on company's bottom line. Via Benzinga Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO September 24, 2024 Novo Nordisk CEO commits to exploring ways to make weight-loss drugs more affordable for U.S. patients after hearing from Congress. Via Benzinga 'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing September 24, 2024 Last week, another Novo executive indicated that Ozempic would "very likely" be included in the 2027 list. Via Benzinga 2 Weight-Loss Stocks That Could Rocket Higher This Year September 24, 2024 Upcoming clinical trial results could push these stocks through the roof before 2024 is finished. Via The Motley Fool Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now September 23, 2024 Corbus Pharmaceuticals received buy ratings from H.C. Wainwright and Oppenheimer, citing the company's diversified pipeline. Via Benzinga Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday September 23, 2024 Novo Nordisk CEO Lars Fruergaard Jørgensen faces a Senate hearing led by Bernie Sanders over the high cost of Ozempic and Wegovy, as U.S. lawmakers push for drug price reductions. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 58 59 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.